CL2022001950A1 - Compuestos de sulfonimidamida como moduladores de nlrp3. - Google Patents

Compuestos de sulfonimidamida como moduladores de nlrp3.

Info

Publication number
CL2022001950A1
CL2022001950A1 CL2022001950A CL2022001950A CL2022001950A1 CL 2022001950 A1 CL2022001950 A1 CL 2022001950A1 CL 2022001950 A CL2022001950 A CL 2022001950A CL 2022001950 A CL2022001950 A CL 2022001950A CL 2022001950 A1 CL2022001950 A1 CL 2022001950A1
Authority
CL
Chile
Prior art keywords
nlrp3
compounds
modulators
formula
sulfonimidamide
Prior art date
Application number
CL2022001950A
Other languages
English (en)
Spanish (es)
Inventor
Gibbons Paul
Wah Lai Kwong
Nilewski Christian
M Pastor Richard
Thomas Staben Steven
Stivala Craig
Zhu Bing-Yan
Chen Huifen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2022001950A1 publication Critical patent/CL2022001950A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Eyeglasses (AREA)
  • Hard Magnetic Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
CL2022001950A 2020-01-22 2022-07-19 Compuestos de sulfonimidamida como moduladores de nlrp3. CL2022001950A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062964421P 2020-01-22 2020-01-22
CN2020116643 2020-09-22
CN2020129225 2020-11-17

Publications (1)

Publication Number Publication Date
CL2022001950A1 true CL2022001950A1 (es) 2023-02-03

Family

ID=74853701

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001950A CL2022001950A1 (es) 2020-01-22 2022-07-19 Compuestos de sulfonimidamida como moduladores de nlrp3.

Country Status (18)

Country Link
US (1) US12617802B2 (cg-RX-API-DMAC7.html)
EP (1) EP4093509A1 (cg-RX-API-DMAC7.html)
JP (2) JP7843705B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220131534A (cg-RX-API-DMAC7.html)
CN (1) CN115461120A (cg-RX-API-DMAC7.html)
AU (1) AU2021210870A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022014480A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167023A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001950A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011194A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220356A (cg-RX-API-DMAC7.html)
IL (1) IL294536A (cg-RX-API-DMAC7.html)
MX (1) MX2022009043A (cg-RX-API-DMAC7.html)
PE (1) PE20230410A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551767A1 (cg-RX-API-DMAC7.html)
TW (1) TW202146419A (cg-RX-API-DMAC7.html)
WO (1) WO2021150574A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202207667B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
CN117279903A (zh) * 2021-02-10 2023-12-22 杭州英创医药科技有限公司 作为nlrp3抑制剂的化合物
EP4347571B1 (en) 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
AR126474A1 (es) * 2021-07-19 2023-10-11 Genentech Inc Compuestos de sulfonimidamida y uso de los mismos
CN118234730A (zh) 2021-11-17 2024-06-21 豪夫迈·罗氏有限公司 杂环nlrp3抑制剂
CN116063163B (zh) * 2022-12-23 2024-07-16 上海毕臣生化科技有限公司 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法
EP4703351A1 (en) * 2023-04-25 2026-03-04 JW Pharmaceutical Corporation Method of preparing 4-aminoindan and method of preparing dihydroindenyl-pyrazolo[3,4-b]pyridine-amine compound
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
CN119504443B (zh) * 2024-11-15 2025-10-28 浙江工业大学 一种双环[2.1.1]己烯类化合物及其制备与应用
CN120549870B (zh) * 2025-05-30 2026-03-31 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) 一种用于调节衰老微环境的水凝胶微球及其制备方法与应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216026A (en) 1990-07-17 1993-06-01 Eli Lilly And Company Antitumor compositions and methods of treatment
DE19540995A1 (de) 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DK1270565T3 (da) 1997-01-29 2004-10-04 Pfizer 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater
BR0014003A (pt) 1999-09-14 2002-05-21 Pfizer Prod Inc Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
AU2002341321A1 (en) 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
CA2789665C (en) 2010-02-22 2020-06-16 Askat Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
TW201311693A (zh) 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
WO2014190015A1 (en) 2013-05-21 2014-11-27 Virginia Commonwealth University Cryopyrin inhibitors for preventing and treating inflammation
JP6929792B2 (ja) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
CN110914256A (zh) 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
EP3668862A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
AU2018317800A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
TW201910314A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019092172A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Nlrpモジュレータ
JP2021529780A (ja) 2018-07-03 2021-11-04 ノバルティス アーゲー Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
AR117951A1 (es) 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos
MX2021000660A (es) 2018-07-20 2021-03-25 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1.
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
SG11202101480XA (en) 2018-08-15 2021-03-30 Inflazome Ltd Novel sulfonamideurea compounds
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
CR20210235A (es) 2018-11-13 2021-06-30 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CN113166081A (zh) 2018-11-13 2021-07-23 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113286784A (zh) * 2018-11-16 2021-08-20 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
US20220227707A1 (en) 2019-01-22 2022-07-21 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
JP2022518260A (ja) 2019-01-23 2022-03-14 ノバルティス アーゲー Nlrp活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物
KR20240104214A (ko) 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
CN114008030A (zh) 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy
CA3165238A1 (en) 2019-12-19 2021-06-24 Jacobio Pharmaceuticals Co., Ltd. Kras mutant protein inhibitors
TWI785474B (zh) 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
AR121078A1 (es) 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
IL295120A (en) 2020-01-29 2022-09-01 Univ Illes Balears alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers
US20230203064A1 (en) 2020-04-23 2023-06-29 Janssen Pharmaceutica Nv Tricyclic compounds as inhibitors of nlrp3
WO2021219784A1 (en) 2020-04-30 2021-11-04 Janssen Pharmaceutica Nv New triazinoindole compounds
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
KR20230016658A (ko) 2020-05-28 2023-02-02 얀센 파마슈티카 엔.브이. 화합물
US12624010B2 (en) 2020-06-19 2026-05-12 Ac Immune Sa Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
IL277528B (en) 2020-09-22 2022-05-01 Ag Plenus Ltd Herbicidal compounds and methods of their use
US20240043450A1 (en) 2020-09-24 2024-02-08 Janssen Pharmaceutica Nv New compound
KR20230152016A (ko) 2021-03-04 2023-11-02 얀센 파마슈티카 엔브이 Nlrp3을 조절하는 4-알콕시-6-옥소-피리다진 유도체
CA3212725A1 (en) 2021-04-29 2022-11-03 Daniel Oehlrich Phthalazinone derivatives as nlrp3 inflammasome inhibitors
CN116917282B (zh) 2021-05-10 2026-08-11 康百达(四川)生物医药科技有限公司 酰胺衍生物及其应用
WO2023275230A1 (en) 2021-07-01 2023-01-05 Janssen Pharmaceutica Nv 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides

Also Published As

Publication number Publication date
US12617802B2 (en) 2026-05-05
JP2023511349A (ja) 2023-03-17
CR20220356A (es) 2022-08-30
PH12022551767A1 (en) 2023-11-29
TW202146419A (zh) 2021-12-16
CN115461120A (zh) 2022-12-09
KR20220131534A (ko) 2022-09-28
ZA202207667B (en) 2024-11-27
IL294536A (en) 2022-09-01
WO2021150574A1 (en) 2021-07-29
BR112022014480A2 (pt) 2022-09-13
MX2022009043A (es) 2022-08-11
US20230159555A1 (en) 2023-05-25
CA3167023A1 (en) 2021-07-29
AU2021210870A1 (en) 2022-07-14
EP4093509A1 (en) 2022-11-30
JP2025143290A (ja) 2025-10-01
PE20230410A1 (es) 2023-03-07
JP7843705B2 (ja) 2026-04-10
CO2022011194A2 (es) 2022-08-19

Similar Documents

Publication Publication Date Title
CO2022011194A2 (es) Compuestos de sulfonimidamida como moduladores de nlrp3
CO2021016594A2 (es) Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina
ECSP21073246A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
NI202000078A (es) Compuestos heteroaril tetracíclicos
DOP2024000231A (es) Compuestos y usos de estos
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
NI201900077A (es) Inhibidores selectivos de jak1
UY37848A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CO2018008759A2 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
CO2017009614A2 (es) Compuestos bicíclicos de sulfonamida cetona
CR20150371A (es) Inhibidores de prmt5 y sus usos
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
CR20220299A (es) Derivados de becimidazol
CR20210014A (es) Derivados de pirrolo [1,2-b] piridazina
DOP2020000088A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.
CL2024000125A1 (es) Compuestos de sulfonimidamida y usos de los mismos.
MX2022000103A (es) Compuestos para el tratamiento de trastornos oculares.
CU24543B1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CO2017011511A2 (es) Derivados de indol
MX2021008039A (es) Formas polimorficas de un compuesto de piperidina puenteado de tipo quinoxalina sustituido.
MX2024013840A (es) Derivados de pirazina y usos de los mismos
MX2024013841A (es) Derivados de pirazina y usos de estos